BRIEF-Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)

Reuters
30 Jul
BRIEF-<a href="https://laohu8.com/S/CRDF">Cardiff Oncology</a> Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)

Cardiff Oncology Inc CRDF.O:

  • CARDIFF ONCOLOGY ANNOUNCES POSITIVE DATA FROM ONGOING RANDOMIZED PHASE 2 FIRST-LINE RAS-MUTATED MCRC CLINICAL TRIAL (CRDF-004)

  • CARDIFF ONCOLOGY INC - TRIAL SHOWS 49% ORR IN 30MG ONVANSERTIB DOSE ARM

  • CARDIFF ONCOLOGY INC - EARLY PFS DATA FAVORS 30MG ONVANSERTIB DOSE ARM

  • CARDIFF ONCOLOGY INC - ONVANSERTIB WELL-TOLERATED, SHOWS DOSE-DEPENDENT RESPONSE

Source text: ID:nGNXVrthT

Further company coverage: CRDF.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10